Anticancer agent 162
Anticancer agent 162 (compound 1d) is an effective anticancer theranostic agent. Anticancer agent 162 induces oncosis of Hela cells with lipophilicity and cytotoxicity selectivity[1].
Product Specifications
CAS Number
2761736-66-5
UNSPSC
12352005
Target
Others
Type
Reference compound
Related Pathways
Others
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/anticancer-agent-162.html
Solubility
10 mM in DMSO
Smiles
O=S([O-])(C(F)(F)F)=O.C1(N=C(C2=C(C3=[N]([Pt+2]45[C-]6=C(C7=[N]5C=CC=C7)C=CC=C6)C=CC=C38)[N]4=CC=C2)C8=N9)=C9C=CC=C1
Molecular Formula
C30H18F3N5O3PtS
Molecular Weight
780.64
References & Citations
[1]Wang W, et al. A Series of Planar Phosphorescent Cyclometalated Platinum (II) Complexes as New Anticancer Theranostic Agents That Induce Oncosis. J Med Chem. 2023 Sep 28;66 (18) :13103-13115.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
GTR15335586 1 Vial
Lentiviral human KRTAP12-2 shRNA (UAS) - Lentiviral human KRTAP12-2 shRNA (UAS, iRFP) (100)
Sign In for Pricing
View Details GTR15157850 1 Vial
Lentiviral mouse Smarca4 shRNA (UAS) - Lentiviral mouse Smarca4 shRNA (UAS, iRFP) (25)
Sign In for Pricing
View Details 
MBS1136585-01 0.02 mg (E-Coli)
Recombinant Mycobacterium avium Uridylate kinase (pyrH)
Sign In for Pricing
View Details MBS1136585-02 0.02 mg (Yeast)
Recombinant Mycobacterium avium Uridylate kinase (pyrH)
Sign In for Pricing
View Details